<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39356444</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>No reduced serum serotonin levels in patients with post-acute sequelae of COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-024-02397-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Approximately 10-20% of patients previously infected with SARS-CoV-2 experience post-acute sequelae of COVID-19 (PASC), presenting with fatigue and neurocognitive dysfunction along various other symptoms. Recent studies suggested a possible role of a virally induced decrease in peripheral serotonin concentration in the pathogenesis of PASC. We set out to verify this finding in an independent and well-defined cohort of PASC patients from our post-COVID-19 outpatient clinic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective case-control study including 34 confirmed PASC patients and 14 healthy controls. Clinical assessment encompassed physician examination as well as questionnaire based evaluation. Eligibility required ongoing symptoms for at least 6 months post-PCR-confirmed infection, relevant fatigue (CFS ≥ 4), and no other medical conditions. Serum serotonin was determined by LC-MS/MS technique.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum serotonin levels in PASC patients did not significantly differ from healthy controls. Most subjects had normal serotonin levels, with no subnormal readings. Subgroup analyses showed no significant differences in serotonin levels based according to predominant fatigue type, high overall fatigue score or depression severity.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We postulate that peripheral serotonin is no reliable biomarker for PASC and that it should not be used in routine diagnostic. Therapy of PASC with serotonin-reuptake inhibitors or tryptophane supplementation should not be based solely on the assumption of lowered serotonin levels.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mathé</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Götz</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. veronika.goetz@uniklinik-freiburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stete</LastName><ForeName>Katarina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walzer</LastName><ForeName>Dietrich</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilger</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfau</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Maike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieg</LastName><ForeName>Siegbert</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Winfried V</ForeName><Initials>WV</Initials><AffiliationInfo><Affiliation>Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Serum serotonin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39356444</ArticleId><ArticleId IdType="doi">10.1007/s15010-024-02397-5</ArticleId><ArticleId IdType="pii">10.1007/s15010-024-02397-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peter RS, Nieters A, Kräusslich HG, et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379: e071050. https://doi.org/10.1136/bmj-2022-071050 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-071050</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Butzin-Dozier Z, Ji Y, Deshpande S, et al. SSRI Use During Acute COVID-19 Infection Associated with Lower Risk of Long COVID Among Patients with Depression. Published online February 6, 2024:2024.02.05.24302352. https://doi.org/10.1101/2024.02.05.24302352</Citation></Reference><Reference><Citation>Sidky H, Hansen KA, Girvin AT, et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. Comput Struct Biotechnol J. 2024;24:115–25. https://doi.org/10.1016/j.csbj.2023.12.045 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2023.12.045</ArticleId><ArticleId IdType="pubmed">38318198</ArticleId><ArticleId IdType="pmc">10839808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AC, Devason AS, Umana IC, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186:4851-4867.e20. https://doi.org/10.1016/j.cell.2023.09.013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId><ArticleId IdType="pmc">11227373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadlier C, Albrich WC, Neogi U, et al. Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID-19. Allergy. 2022;77:1623–5. https://doi.org/10.1111/all.15253 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15253</ArticleId><ArticleId IdType="pubmed">35150456</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao ML, Gross G, Strebel B, et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiat. 1994;35:151–63. https://doi.org/10.1016/0006-3223(94)91147-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-3223(94)91147-9</ArticleId><ArticleId IdType="pubmed">7909693</ArticleId></ArticleIdList></Reference><Reference><Citation>Korse CM, Buning-Kager JCGM, Linders TC, et al. A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clin Chim Acta. 2017;469:130–5. https://doi.org/10.1016/j.cca.2017.04.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2017.04.001</ArticleId><ArticleId IdType="pubmed">28385629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>